We found higher numbers of exhausted T cells expressing several inhibitory receptors, including PD-1, CTLA-4, TIM-3, and LAG-3, that, upon binding to their ligands expressed in cancer cells, gradually reduce their effector function and proliferation [49], thus influencing the nanovaccine treatment outcome. This evidence concerns the gene HAVCR2 and cancer.